Search Results
Jan 13, 2026, 08:05 ET Kye Pharmaceuticals Announces Licensing and Distribution Agreement with Neurim Pharmaceuticals for SLENYTO® in Canada
aged 1 to 17 years, is about 2% (1 in 50) and is equivalent to about 150,000 cases in Canada in 2025 [1, 2]. Smith-Magenis syndrome (SMS) is a very rare (1:15,000 to 1:25,000 births) genetic neurodevelopmental disorder that affects behaviors, emotions and learning processes and roughly 300–500 children
More news about: Kye Pharmaceuticals Inc.
Jan 13, 2026, 08:01 ET Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
receiving Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and the FDA Orphan Drug Designations. Copper histidinate has also been granted Orphan Designation by the European Medicines Agency.About Menkes Disease Menkes disease is a rare X-linked recessive pediatric disease caused
More news about: Sentynl Therapeutics
Jan 13, 2026, 08:00 ET Orsini Selected as Specialty Pharmacy Partner for Cytokinetics's MYQORZO™ (aficamten)
care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including
More news about: Orsini
Jan 13, 2026, 08:00 ET Randall W. Atkins Appointed to National Coal Council
coal, rare earth and critical minerals in Wyoming. Its executive offices are in Lexington, Kentucky, with operational offices in Charleston, West Virginia and Sheridan, Wyoming. The Company currently has four active metallurgical coal mining complexes in Central Appalachia and one development rare earth
More news about: Ramaco Resources, Inc.
Jan 13, 2026, 08:00 ET Major League Table Tennis Drives Record Audience Growth as 2025-26 Season Elevates the Sport Nationwide
MLTT rankings, a rare milestone in mixed-gender professional sports featured by CNN this week, and partnered with
More news about: Major League Table Tennis
Jan 13, 2026, 08:00 ET Johnson & Johnson elevates leadership in depression with new data at 2026 American College of Neuropsychopharmacology Annual Meeting
high fever, confusion, changes in your breathing, heart rate, and blood pressure, stiff muscles, and increased sweating; these may be symptoms of a rare but potentially fatal condition. Contact your healthcare provider or go to the emergency room if you experience signs and symptoms of NMS.Uncontrolled
More news about: Johnson & Johnson
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
Affiliated Hospital, Zhejiang University School of Medicine, under the leadership of Dr. Zhi-Ying Wu, head of the Department of Medical Genetics/Center for Rare Diseases. This Phase II trial is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the
More news about: Ractigen Therapeutics
Jan 13, 2026, 07:17 ET Choura Events is expanding its presence into Northern California
background includes leadership roles with TPC Monterey, The Quail, and luxury resort properties across the West Coast."Monterey County has a rare combination of history, natural beauty, and emotional connection when it comes to live events," Henderson said. "Our goal is to honor that legacy while
More news about: Choura Events
Jan 13, 2026, 07:04 ET Converge Bio raises $25M to bring generative AI drug discovery to every biotech and pharmaceutical company
to identify where AI can deliver real results for them today, and provide them with our validated tools to get there.""Converge has something rare in this space: real commercial traction and strong scientific results," said Andrew Hedin, Partner at Bessemer Venture Partners. "The team has built
More news about: Converge Bio
Jan 13, 2026, 07:00 ET Magnet Biomedicine Expands Leadership with Appointment of Nick Vlahakis, M.B.B.S., as Chief Medical Officer
cross-functional expertise in strategic drug development, regulatory strategy and clinical study execution from preclinical to Phase 3 trials – spanning rare disease, immunology, and oncology programs. Previously, he served as Chief Medical Officer at CohBar, Inc., where he led translational and clinical
More news about: Magnet Biomedicine
Jan 13, 2026, 06:46 ET Tradr Launches Leveraged ETFs on Critical Metals, Ondas Holdings, UiPath and USA Rare Earth
USAX) – tracks USA Rare Earth Inc. (Nasdaq: USAR)"After 47 fund launches in 2025, we are excited to continue the momentum into 2026," said Matt Markiewicz, Head
More news about: Tradr ETFs
Jan 13, 2026, 04:18 ET ESTEVE acquisirà la business unit Infusion Specialty Therapies di TerSera Therapeutics, espandendo la presenza negli Stati Uniti
terapeutiche principali dell'oncologia e delle malattie rare". Questa operazione rafforza la crescita di ESTEVE negli Stati Uniti, una crescita iniziata con l'acquisizione nel 2024 di un'azienda specializzata in malattie rare e ultra-rare nelle aree dell'endocrinologia e dell'oncoendocrinologia.
More news about: ESTEVE
Jan 13, 2026, 03:45 ET ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence
sharpen our focus on our core therapeutic areas of oncology and rare disease." This deal reinforces ESTEVE's growth in the United States, a growth that began with the acquisition in 2024 of a business specialized in rare and ultra-rare diseases in the areas of endocrinology and onco-endocrinology.
More news about: ESTEVE
Jan 13, 2026, 03:00 ET Save Ohio Parks and environmental advocates warn against expanding frack leases under Ohio state parks and public lands
endangered Indiana bats, eastern hellbenders and eastern black bears;Methane gas emissions from natural gas production and utility use that cause rare cancers in young children, increase respiratory disease and accelerate climate warming and climate change.Speakers peppered their testimony
More news about: Save Ohio Parks
Jan 13, 2026, 03:00 ET n-Lorem and EspeRare annoncent une collaboration européenne pour élargir l'accès aux thérapies ASO individualisées pour les maladies génétiques rares
à des traitements grâce à notre plateforme ASO», déclare Sarah Glass, Ph.D., Directrice des opérations de la Fondation n-Lorem. « La communauté nano-rare a des besoins immenses à l'échelle mondiale. Cette collaboration représente une étape cruciale pour étendre notre mission au-delà des États-Unis. Les
More news about: EspeRare Foundation
Jan 12, 2026, 19:54 ET Abbisko Therapeutics Announces FDA Acceptance of the NDA for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
months further showed ORR continued to increase over time among patients treated with pimicotinib from the beginning of the study.TGCT is a rare, locally aggressive tumor occurring in or around the joint leading to progressive swelling, stiffness and reduced mobility of the affected joint, significantly
More news about: Abbisko
Jan 12, 2026, 16:05 ET BioMarin Appoints Arpit Davé Chief Digital and Information Officer
development to our manufacturing and commercial organizations, now and in the future.""I have long admired BioMarin's dedication to people living with rare diseases and I am excited to work as part of this team to create undeniable value for patients, employees and shareholders," said Mr. Davé. "I am honored
More news about: BioMarin Pharmaceutical Inc.
Jan 12, 2026, 14:00 ET Health Enterprise Partners Appoints Healthcare Industry Veteran Roland Lyon as Operating Partner
he led a $4.2 billion enterprise supporting more than 6,000 employees and delivering care to hundreds of thousands of members."Roland brings a rare and highly valuable combination of payer and provider experience that will deliver immediate impact across our portfolio and strategic network," said
More news about: Health Enterprise Partners
Jan 12, 2026, 13:43 ET n-Lorem and EspeRare announce European collaboration to expand access to individualized ASO Therapies for Rare Genetic Diseases
patients with rare genetic diseases. The collaboration aims to address the regulatory, operational, and diagnostic barriers that limit access to personalized genetic medicines outside the United States. The partnership will initially focus on pursuing treatment of a small number of nano-rare patients who
More news about: EspeRare Foundation
Jan 12, 2026, 13:00 ET Brighton Jones Promotes Melinda Torres to Chief Marketing Officer
investment in brand as a strategic tool to support our people, our clients, and our long-term vision and purpose," said Torres."Melinda brings a rare ability to connect brand, client experience, and business strategy in a way that feels authentic to who we are," said Jon Jones, CEO and co-founder
More news about: Brighton Jones
Jan 12, 2026, 11:17 ET Coinme Names Hazen Baron as General Counsel
expansion, enterprise partnership agreements and navigating the evolving federal and state regulatory landscape for digital assets. "Hazen brings a rare combination of legal acumen and operational experience in regulated financial services," said Neil Bergquist, CEO and co-founder of Coinme. "With over
More news about: Coinme
Jan 12, 2026, 11:15 ET Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted its broad portfolio progress at the 44th Annual J.P. Morgan Healthcare Conference. A copy of the slide
More news about: Biohaven Ltd.
Jan 12, 2026, 10:53 ET Metallium Announces Sponsored Level 1 ADR Program with Bank of New York
The company's patented Flash Joule Heating (FJH) technology enables the extraction of high-value materials, including gallium, germanium, antimony, rare earths elements and gold, from feedstocks such as refinery scrap, e-waste and monazite.
More news about: MTM Critical Metals Ltd.
Jan 12, 2026, 10:35 ET Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
registration-directed study designs that prioritize objective response rates as critical catalysts for major capital allocation in the fight against rare and resistant cancers.Oncolytics Biotech Inc. (NASDAQ: ONCY) is advancing pelareorep, an investigational immunotherapy, toward potential
More news about: USA News Group
Jan 12, 2026, 10:34 ET Club Offers for Travel Enthusiasts in Canada
all transportation. $3999—MALDIVES ALL-INCLUSIVE FOR 5 NIGHTSDiscover this family-friendly oasis in North Malé Atoll, a rare find among the luxury resorts in the area. Club Members save over $5000. Up to two adults and two children are included in the price. $1799—SINGAPORE
More news about: Travelzoo